Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder

Reiji Yoshimura, Taro Kishi, Hikaru Hori, Atsuko Ikenouchi-Sugita, Asuka Katsuki, Wakako Umene-Nakano, Nakao Iwata, Jun Nakamura

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: Only two-thirds of depressive patients respond to antidepressant treatment. In recent years, addition of an atypical antipsychotic drug to ongoing treatment with an antidepressant has been considered effective and well-tolerated. In the present study, we compared the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depression. Subjects and methods: Twenty-four patients who met the DSM-IV criteria for major depressive disorder who did not at least two different classes of antidepressants were enrolled in the study. Nine were male and thirteen were female, and their ages ranged from 28 to 66 (mean ± SD = 39 ± 12) years. Patients were prescribed paroxetine (n= 11) or sertraline (n= 13) for 4. weeks. Then, those whose scores on the 17-item Hamilton Rating Scale for Depression (HAMD17) decreased below 50% received adjunctive therapy of aripiprazole for 4. weeks. Results: Although the use of either combination treatment decreased the HAMD17 scores compared to the respective monotherapy, there was no significant difference in HAMD17 scores between the paroxetine plus aripiprazole group and sertraline plus aripiprazole group. Conclusion: Aripiprazole augmentation therapy with paroxetine or sertraline was equally effective and tolerated in patients with refractory major depressive order.

Original languageEnglish
Pages (from-to)355-357
Number of pages3
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume39
Issue number2
DOIs
Publication statusPublished - 03-12-2012

Fingerprint

Sertraline
Paroxetine
Major Depressive Disorder
Antidepressive Agents
Treatment-Resistant Depressive Disorder
Therapeutics
Diagnostic and Statistical Manual of Mental Disorders
Antipsychotic Agents
Aripiprazole
Depression

All Science Journal Classification (ASJC) codes

  • Biological Psychiatry
  • Pharmacology

Cite this

Yoshimura, Reiji ; Kishi, Taro ; Hori, Hikaru ; Ikenouchi-Sugita, Atsuko ; Katsuki, Asuka ; Umene-Nakano, Wakako ; Iwata, Nakao ; Nakamura, Jun. / Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2012 ; Vol. 39, No. 2. pp. 355-357.
@article{da37959fcb2247f9b80b1e818e9e7ddd,
title = "Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder",
abstract = "Objective: Only two-thirds of depressive patients respond to antidepressant treatment. In recent years, addition of an atypical antipsychotic drug to ongoing treatment with an antidepressant has been considered effective and well-tolerated. In the present study, we compared the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depression. Subjects and methods: Twenty-four patients who met the DSM-IV criteria for major depressive disorder who did not at least two different classes of antidepressants were enrolled in the study. Nine were male and thirteen were female, and their ages ranged from 28 to 66 (mean ± SD = 39 ± 12) years. Patients were prescribed paroxetine (n= 11) or sertraline (n= 13) for 4. weeks. Then, those whose scores on the 17-item Hamilton Rating Scale for Depression (HAMD17) decreased below 50{\%} received adjunctive therapy of aripiprazole for 4. weeks. Results: Although the use of either combination treatment decreased the HAMD17 scores compared to the respective monotherapy, there was no significant difference in HAMD17 scores between the paroxetine plus aripiprazole group and sertraline plus aripiprazole group. Conclusion: Aripiprazole augmentation therapy with paroxetine or sertraline was equally effective and tolerated in patients with refractory major depressive order.",
author = "Reiji Yoshimura and Taro Kishi and Hikaru Hori and Atsuko Ikenouchi-Sugita and Asuka Katsuki and Wakako Umene-Nakano and Nakao Iwata and Jun Nakamura",
year = "2012",
month = "12",
day = "3",
doi = "10.1016/j.pnpbp.2012.07.008",
language = "English",
volume = "39",
pages = "355--357",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",
number = "2",

}

Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder. / Yoshimura, Reiji; Kishi, Taro; Hori, Hikaru; Ikenouchi-Sugita, Atsuko; Katsuki, Asuka; Umene-Nakano, Wakako; Iwata, Nakao; Nakamura, Jun.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 39, No. 2, 03.12.2012, p. 355-357.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depressive disorder

AU - Yoshimura, Reiji

AU - Kishi, Taro

AU - Hori, Hikaru

AU - Ikenouchi-Sugita, Atsuko

AU - Katsuki, Asuka

AU - Umene-Nakano, Wakako

AU - Iwata, Nakao

AU - Nakamura, Jun

PY - 2012/12/3

Y1 - 2012/12/3

N2 - Objective: Only two-thirds of depressive patients respond to antidepressant treatment. In recent years, addition of an atypical antipsychotic drug to ongoing treatment with an antidepressant has been considered effective and well-tolerated. In the present study, we compared the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depression. Subjects and methods: Twenty-four patients who met the DSM-IV criteria for major depressive disorder who did not at least two different classes of antidepressants were enrolled in the study. Nine were male and thirteen were female, and their ages ranged from 28 to 66 (mean ± SD = 39 ± 12) years. Patients were prescribed paroxetine (n= 11) or sertraline (n= 13) for 4. weeks. Then, those whose scores on the 17-item Hamilton Rating Scale for Depression (HAMD17) decreased below 50% received adjunctive therapy of aripiprazole for 4. weeks. Results: Although the use of either combination treatment decreased the HAMD17 scores compared to the respective monotherapy, there was no significant difference in HAMD17 scores between the paroxetine plus aripiprazole group and sertraline plus aripiprazole group. Conclusion: Aripiprazole augmentation therapy with paroxetine or sertraline was equally effective and tolerated in patients with refractory major depressive order.

AB - Objective: Only two-thirds of depressive patients respond to antidepressant treatment. In recent years, addition of an atypical antipsychotic drug to ongoing treatment with an antidepressant has been considered effective and well-tolerated. In the present study, we compared the efficacy between paroxetine and sertraline augmented with aripiprazole in patients with refractory major depression. Subjects and methods: Twenty-four patients who met the DSM-IV criteria for major depressive disorder who did not at least two different classes of antidepressants were enrolled in the study. Nine were male and thirteen were female, and their ages ranged from 28 to 66 (mean ± SD = 39 ± 12) years. Patients were prescribed paroxetine (n= 11) or sertraline (n= 13) for 4. weeks. Then, those whose scores on the 17-item Hamilton Rating Scale for Depression (HAMD17) decreased below 50% received adjunctive therapy of aripiprazole for 4. weeks. Results: Although the use of either combination treatment decreased the HAMD17 scores compared to the respective monotherapy, there was no significant difference in HAMD17 scores between the paroxetine plus aripiprazole group and sertraline plus aripiprazole group. Conclusion: Aripiprazole augmentation therapy with paroxetine or sertraline was equally effective and tolerated in patients with refractory major depressive order.

UR - http://www.scopus.com/inward/record.url?scp=84867004841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867004841&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2012.07.008

DO - 10.1016/j.pnpbp.2012.07.008

M3 - Article

C2 - 22813840

AN - SCOPUS:84867004841

VL - 39

SP - 355

EP - 357

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

IS - 2

ER -